Advanced Search:
Equity Index

DBV.PA - DBV TECHNOLOGIES

€1.33  0 (0%)

Updated: 11:46 May 5, 2024 EST

Next Session's AI Forecast

78.91%

Avg. Accuracy (AI)

€1.02

Next Week's AI Forecast

66.67%

Trend's Accuracy (AI)

€0.98

DBV TECHNOLOGIES's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

DBV TECHNOLOGIES - HISTORICAL DATA 6M

  • Last price

    €1.33

  • Daily change

    €0

  • Previous Close

    €1.331

  • Last Updated

    11:46 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.13 -0.54 -0.53 -0.39 -0.35

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.96 1.64 2.2 2.41 2.32

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
0% 12.5% 14.81% 3.23%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
1.21 0% 1.21 -5.47% 1.28 -18.99% 1.58

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.5 50 1 33.33

DBV TECHNOLOGIES Technical Analysis News

DBV TECHNOLOGIES

177-181 Avenue Pierre Brossolette
Montrouge 92120
France
33 1 55 42 78 78
https://www.dbv-technologies.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 104
Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Corporate Governance

DBV Technologies S.A.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 1; Compensation: 10.

DBV TECHNOLOGIES'S HOLDERS RANK

List of holders with stock participation in DBV TECHNOLOGIES.

Holder Rank Holder Shares Date Reported % Out Value